Physician profile
Heather Schrof
NPI 1578656831
$2,523.21
in general payments reported to CMS, 2019-2025
22 companies · $803 in 2025
The $803 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $214 · 2023: $753 · 2024: $753 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $455.19 | 2023-2024 | Watchman Flx |
| Novo Nordisk INC | $439.37 | 2022-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $318.49 | 2023-2025 | Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $250.43 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Eisai INC. | $157.35 | 2025 | |
| Lilly USA, LLC | $154.88 | 2022-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $94.52 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $94.21 | 2022-2023 | Hetlioz, Fanapt |
| Astellas Pharma US INC | $85.45 | 2024-2025 | Veozah |
| Intuitive Surgical, INC. | $84.94 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $71.48 | 2024 | Breztri, Airsupra |
| Pfizer INC. | $69.39 | 2022-2023 | |
| Exact Sciences Corporation | $43.81 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $35.10 | 2025 | Korlym |
| Amgen INC. | $32.16 | 2023-2025 | Prolia, Evenity, Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $27.77 | 2023 | Horizant |
| Phadia US INC. | $22.71 | 2024 | Immunocap |
| Sanofi Pasteur INC. | $21.16 | 2023 | |
| Xeris Pharmaceuticals, INC. | $18.95 | 2025 | Gvoke Hypopen |
| Abiomed | $17.77 | 2023 | Impella |
| Sumitomo Pharma America, INC. | $14.05 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $14.03 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Schrof listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.